Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial Infarction  by Epstein, Andrew E. et al.
Journal of the American College of Cardiology Vol. 62, No. 21, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.05.086Wearable Cardioverter-Defibrillator Use
in Patients Perceived to Be at High Risk
Early Post-Myocardial Infarction
Andrew E. Epstein, MD,* William T. Abraham, MD,y Nicole R. Bianco, PHD,z Karl B. Kern, MD,x
Michael Mirro, MD,k Sunil V. Rao, MD,{ Edward K. Rhee, MD,# Scott D. Solomon, MD,**
Steven J. Szymkiewicz, MDz
Philadelphia and Pittsburgh, Pennsylvania; Columbus, Ohio; Tucson and Phoenix, Arizona;
Fort Wayne, Indiana; Durham, North Carolina; and Boston, MassachusettsFrom the *C
sylvania, P
Department
burgh, Penn
of Arizona,
{Division o
Center, Du
Hospital an
cular Medi
Massachuse
tronik, BostObjectives Tardiovascular Division, D
hiladelphia, Pennsylvani
of Medicine, Ohio State
sylvania; xDivision of Ca
Tucson, Arizona; kPar
f Cardiology, Departm
rham, North Carolina; #
d Medical Center, Phoen
cine, Department of M
tts. Dr. Epstein has recei
on Scientiﬁc, Medtronic,he aim of this study was to describe usage of the wearable cardioverter-deﬁbrillator (WCD) during mandated
waiting periods following myocardial infarction (MI) for patients perceived to be at high risk for sudden cardiac
arrest (SCA).Background Current device guidelines and insurance coverage require waiting periods of either 40 days or 3 months before
implanting a cardioverter-deﬁbrillator post-myocardial infarction (MI), depending on whether or not acute
revascularization was undertaken.Methods We assessed characteristics of and outcomes for patients who had a WCD prescribed in the ﬁrst 3 months post-MI.
The WCD medical order registry was searched for patients who were coded as having had a “recent MI with ejection
fraction 35%” or given an International Classiﬁcation of Diseases, Ninth Revision 410.xx diagnostic code (acute
MI), and then matched to device-recorded data.Results Between September 2005 and July 2011, 8,453 unique patients (age 62.7  12.7 years, 73% male) matched
study criteria. A total of 133 patients (1.6%) received 309 appropriate shocks. Of these patients, 91% were
resuscitated from a ventricular arrhythmia. For shocked patients, the left ventricular ejection fraction (LVEF)
was 30% in 106, 30% to 35% in 17, >36% in 8, and not reported in 2 patients. Of the 38% of patients not
revascularized, 84% had a LVEF 30%; of the 62% of patients revascularized, 77% had a LVEF 30%. The median
time from the index MI to WCD therapy was 16 days. Of the treated patients, 75% received treatment in the ﬁrst
month, and 96% within the ﬁrst 3 months of use. Shock success resulting in survival was 84% in nonrevascularized
and 95% in revascularized patients.Conclusions During the 40-day and 3-month waiting periods in patients post-MI, the WCD successfully treated SCA in 1.4%, and
the risk was highest in the ﬁrst month of WCD use. The WCD may beneﬁt individual patients selected for high risk of
SCA early post-MI. (J Am Coll Cardiol 2013;62:2000–7) ª 2013 by the American College of Cardiology FoundationSee page 2008Sudden cardiac arrest (SCA) and sudden cardiac death
(SCD) are feared events early post-myocardial infarction
(MI) (1). Whereas implantable cardioverter-deﬁbrillators
(ICDs) have become the cornerstone for both primary andepartment of Medicine, University of Penn-
a; yDivision of Cardiovascular Medicine,
University, Columbus, Ohio; zZOLL, Pitts-
rdiology, Department of Medicine, University
kview Health System, Fort Wayne, Indiana;
ent of Medicine, Duke University Medical
Eller Congenital Heart Center, St. Joseph’s
ix, Arizona; and the **Division of Cardiovas-
edicine, Harvard Medical School, Boston,
ved honoraria and research support from Bio-
and St. Jude Medical; has been a consultant forsecondary SCD prevention, current guidelines proscribe
ICD therapy for 40 days or 3 months post-MI, dependingZOLL Medical; received research grants from Biotronik, Boston Scientiﬁc, Med-
tronic, and St. Jude Medical; and received fellowship support from Boston Scientiﬁc,
Medtronic, and St. Jude Medical. Dr. Abraham has been a consultant for Biotronik,
Medtronic, and St. Jude Medical. Drs. Bianco and Szymkiewicz are employees of
ZOLL. Dr. Kern has been a consultant for PhysioControl and ZOLL; and has been
on the Science Advisory Board of ZOLL Medical. Dr. Mirro has been a consultant
for ZOLL, McKesson, St. Jude Medical, and iRhythm. Dr. Rao has been
a consultant for and received honoraria from ZOLL. Dr. Rhee has been a consultant
for and has received honoraria from ZOLL.
Manuscript received March 21, 2013; revised manuscript received May 6, 2013,
accepted May 22, 2013.
Abbreviations
and Acronyms
AED = automated external
deﬁbrillator
ICD = implantable
cardioverter-deﬁbrillator
LVEF = left ventricular
ejection fraction
MVT = monomorphic
ventricular tachycardia
OMT = optimized medical
therapy
PMVT = polymorphic
ventricular tachycardia
SCA = sudden cardiac arrest
SCD = sudden cardiac death
SSDMF = Social Security
Death Master File
VF = ventricular ﬁbrillation
VFl = ventricular ﬂutter
WCD = wearable
cardioverter-deﬁbrillator
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2001on whether or not patients undergo acute revascularization
(2,3). Nevertheless, although the risk of SCA and death
early post-MI is large, clinical trials have failed to demon-
strate a mortality beneﬁt from the early use of ICDs. The-
DINAMIT (Deﬁbrillator in Acute Myocardial Infarction
Trial) (4) and the IRIS (Immediate Risk Stratiﬁcation
Improves Survival) studies (5) randomized patients early post-
MI to continued optimized medical therapy (OMT) alone or
with an ICD, and neither study showed a beneﬁt from ICD
therapy.
As a consequence of these clinical trial data, waiting
periods of 40 days post-MI if no revascularization was
undertaken, or 3 months when percutaneous or surgical
intervention was done have become standard practice before
ICD implantation, and are endorsed in the ACC/AHA/
HRS device-based therapy guidelines (2). Furthermore, the
Centers for Medicare & Medicaid Services accepted these
waiting periods as being necessary for reimbursement as
dictated by a National Coverage Determination on ICD
implantation (3). However, there remain patients post-MI
perceived to be at high risk for SCD within these waiting
periods, and consideration for ICD treatment is complicated
by tension between clinical judgment, clinical trial data,
and reimbursement rules. The present study describes the
characteristics and outcomes of patients who were prescribed
a wearable cardioverter-deﬁbrillator (WCD) (LifeVest, ZOLL,
Pittsburgh, Pennsylvania) to treat potentially fatal ventric-
ular arrhythmias during the 40-day and 3-month waiting
periods in high-risk patients post-MI.
Methods
The WCD medical order database was searched for patients
who were prescribed the device between September 27,
2005, and July 13, 2011. All patients prescribed a WCD
after market release in the United States are entered into
a database maintained by the manufacturer for regulatory,
reimbursement, and tracking purposes. The database
contains indications, baseline demographics (age and sex),
compliance, end of use reasons, and events. All patients
signed consent to use their data for quality monitoring,
healthcare operation activities, and/or research, and all data
were de-identiﬁed. The institutional review board at the
University of Pennsylvania exempted this study from review.
Patient use and compliance were calculated using the
patient-use data ﬂags stored by the WCD monitor and
downloaded to a secure server. Clinical data were extracted
from the medical documents supplied to ZOLL for reim-
bursement purposes. To ﬁnd recent MI patients, the data-
base was searched for patients who were coded as having had
a “recent MI with ejection fraction 35%” or given an
International Classiﬁcation of Diseases, Ninth Revision
410.XX diagnostic code (acute MI), and then matched to
device-recorded data. Recordings of all treated arrhythmias
from the WCD were individually overread to verify the
arrhythmia diagnosis (A.E.E.). Each was classiﬁed asmonomorphic ventricular tachy-
cardia (MVT), ventricular ﬂutter
(VFl), polymorphic VT (PMVT),
or ventricular ﬁbrillation (VF).
Follow-up was through the data-
base and the Social Security Death
Master File (SSDMF), with the
latter limited after 2012 when
protected state death records
were removed from the SSDMF
database.
Wearable cardioverter-deﬁbrillator.
The WCD consists of 3 deﬁbril-
lation electrode pads, 4 sensing
electrodes, a vibration box, and
a deﬁbrillation unit incorporated
into a lightweight patient-worn
vest. The vest holds monitoring
electrodes against the chest by
tension from an elastic belt. The
deﬁbrillation electrodes are posi-
tioned for apex-to-posterior deﬁ-
brillation. The vest comes in
multiple sizes, and the chest straps and elastic belt can be
adjusted to accommodate the chest size and weight of the
patient. Arrhythmia detection threshold rates are program-
mable, with a VF zone programmable between 120 and
250 beats/min, and a VT zone programmable between
120 beats/min and the VF detection rate. When an
arrhythmia is detected and after a 10-s delay, an escalating
alarm sequence starts with vibrational pulses against the skin
and proceeds to add audible alerts and voice prompts. During
the alarm sequence, if the response buttons are not pressed to
withhold treatment, up to 5 150-J biphasic shocks are deliv-
ered and the electrocardiogram stored. The WCD description
and arrhythmia algorithm have been described elsewhere in
detail (6,7). Event data were reviewed and shocks deemed
appropriate if they occurred during sustained (>30 s) VT/VF
and inappropriate if not. Inappropriate shocks were further
analyzed for the cause of inappropriate detection and the
reason for lack of proper response button use.
Statistical analysis. Data are presented as means  SD,
with medians, or range for skewed distributions. Actuarial
event survival curves were generated according to Kaplan-
Meier analysis. For analytical purposes, all appropriate
shocks and arrhythmias occurring within 24 h of the index
arrhythmia were considered 1 event (“shock event”). Inap-
propriate shock events were all shocks occurring within 24 h
of the index inappropriate shock.
Results
Between September 27, 2005, and July 13, 2011, a WCD
was prescribed for 8,678 patients post-MI. Of those, 225
were not ﬁtted with the device or did not wear it due to
death, a deteriorating condition, insurance noncoverage,
Figure 1 Timing of WCD Shock Events
The time by month after wearable cardioverter-deﬁbrillator (WCD) treatment was
initiated to time of shock events is shown. See text for discussion.
Table 1 Recent MI Patients Prescribed a WCD
All Patients
(N ¼ 8,678)
Patients Fitted and Wearing WCD
(n ¼ 8,453)
Patients Treated for VT/VF
(n ¼ 133)
Male, % 73 73 83
Age, yrs 62.7  12.7 62.6  12.7 63.0  12.2
Median WCD use Not applicable 57 days 15 days
Average LVEF, % Data not available Data not available 23.8  8.8
Revascularized post-MI, % Data not available Data not available 62
Values are % or mean  SD.
LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia; WCD ¼ wearable
cardioverter-deﬁbrillator.
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2002implantation of an ICD, or for unknown reasons, leaving
8,453 patients who were ﬁtted with a WCD and who wore
it for at least 15 min. As shown in Table 1, the mean age was
62.7  12.7 years, and 73% were men. The mean time from
MI to WCD prescription was 9  9 days. The mean length
of use was 69  61 days (median 57 days), and median daily
use was 21.8 h.
Of these 8,453 patients, 133 (1.6%) patients received
appropriate shocks during 146 shock events. Of the 309
appropriate shocks delivered during the 146 shock events
as deﬁned in the preceding text, 252 successfully terminated
VT/VF, 9 led to asystole, 41 were unsuccessful, 1 each
resulted in nonsustained VT and supraventricular tachy-
cardia, and rhythm outcomes were unknown in 5. From an
individual event perspective, 134 occurred in 121 patients
that resulted in survival (conscious arrival to an emergency
room, or did not go); 12 patients did not survive (92%
survival per event, and 91% per patient). Of those initial
survivors, 3 died within 2 days after shock delivery, and 41
died at a time remote from shock delivery (3 days). The
average number of appropriate shocks per event was 2.1 
2.8 (range 1 to 18). VT was not consistently detected in 2
additional events, due to the rate falling below the VT
threshold; neither patient survived. A third VT/VF event
was not detected due to signal artifact obscuring the elec-
trocardiogram signal, and this event also resulted in death.
Bradycardia or asystole events not associated with VT/VF
were responsible for 34 additional deaths (0.4% of patients)
while wearing the WCD. For shocked patients, the left
ventricular ejection fraction (LVEF) was 30% in 106, 30%
to 35% in 17, >36% in 8, and not reported in 2 patients.
Of the 38% patients not revascularized, 84% had
a LVEF 30%. Of the 62% patients who were revascular-
ized, 77% had a LVEF 30%.
Ninety-nine patients received 114 inappropriate shocks
(shocks not associated with VT/VF). None of the inap-
propriate shocks induced arrhythmias, and there were no
burns or other shock sequelae beyond the immediate pain.
These occurred during 102 shock events and, in combina-
tion with a universal lack of proper response button use to
prevent shock, were due to electrical oversensing [15], noise
artifact [62], detection of supraventricular tachycardia [21],
nonsustained VT [3], and other causes [1]. The inappro-
priate shock rate was 0.006 shocks per patient month of use.For those patients who received an appropriate shock, the
mean length of WCD use was 31  37 days (median
15 days), and the length of use after appropriate shock was
8  18 days (median 3 days). The average time from WCD
prescription to ﬁrst shock delivery was 22  32 days (median
9 days) (Fig. 1), with 75% of ﬁrst shocks occurring in the
ﬁrst 30 days and 96% occurring in the ﬁrst 90 days. The
average time from the index MI to ﬁrst treatment was
30  37 days (median 16 days), and from revascularization
to ﬁrst treatment 26  37 days (median 14 days). The time
from MI to WCD prescription was 7 days for both non-
revascularized and revascularized patients.
When recordings were analyzed according to arrhythmia
diagnosis at onset and treatment, 66 patients had MVT at
onset and at treatment (Fig. 2), 28 had VF at onset and at
treatment (Fig. 3), 17 had PMVT that degenerated to VF
at treatment, 11 patients had PMVT that stabilized into
a MVT or VFl at treatment, 10 had VT or VFl that
degenerated into VF at treatment, and 1 had VF at onset
that regularized into VFl at treatment. In 18 instances, the
actual arrhythmia onset was not captured, with the recording
starting during arrhythmia. Because all of the latter were
VT, onset for these patients was classiﬁed as VT. For those
with electrocardiogram recordings showing the actual onset
of the ﬁrst shocked arrhythmia (n ¼ 115), the median time
Figure 2 WCD Recording of Cardiac Arrest Due to MVT
Recordings from resuscitation of cardiac arrest from monomorphic ventricular tachycardia (MVT) showing arrhythmia onset (A) and cardioversion 45 s later (B). WCD¼ wearable
cardioverter-deﬁbrillator.
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2003from onset to therapy was 47 s (25th percentile 44 s, 75th
percentile 76 s). Reasons why arrhythmia onset was not
available included noise artifact, removal of the battery by
a conscious patient, and slow VT. There was a wide varia-
tion because some patients (who remained conscious) pre-
vented therapy by holding the response buttons until they
lost consciousness or halted the inhibition.
For those treated patients who died, the average time from
WCD start to death was 202  294 days (median 81 days),
and average time from ﬁrst treatment to death was 175  297
days (median 29 days). Follow-up time to assess mortality forthose not dead was 900  456 days. The actuarial survival
analysis of all patients treated with a WCD showed that in
the 3-, 6-, and 12-month intervals following the WCD
application, cumulative survival was 96%, 94%, and 93%,
respectively (Fig. 4A). The actuarial survival analysis of
patients treated with appropriate shocks showed that in the
same 3-, 6-, and 12-month intervals, cumulative survival was
73%, 70%, and 65%, respectively (Fig. 4B). For survival
analysis stratiﬁed by rhythm, because the distinction between
MVT and VFl and between PMVT and VF is somewhat
arbitrary, they were grouped as VT/VFl and PMVT/VF,
Figure 3 WCD Recording of Cardiac Arrest Due to VF
Recordings from resuscitation of cardiac arrest from ventricular ﬁbrillation (VF) showing arrhythmia onset (A) and deﬁbrillation 41 s later (B). WCD ¼ wearable cardioverter-
deﬁbrillator.
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2004respectively. When analyzed according to the rhythm at onset,
survival was 63% for those with VT/VFl and 67% for those
treated for PMVT/VF (p ¼ NS). When analyzed according
to the treated rhythm, survival was 67% for those with VT/
VFl and 62% for those treated for PMVT/VF (p ¼ NS).
Discussion
This study shows that during mandatory ICD implantation
waiting times (40 days or 3 months, depending on whetheror not revascularization was performed) in patients perceived
to be at high risk for SCA post-MI, the WCD successfully
treats VT/VF. The risk of VT/VF was highest in the ﬁrst
month of WCD use, with a median time until ﬁrst treat-
ment of 9 days, and 1.4% of patients were resuscitated by the
WCD in the early weeks post-MI. Of treated patients, 75%
received therapy in the ﬁrst month of use, and 96% in the
ﬁrst 3 months of use.
To place these data in perspective, the current study may
be compared with the VALIANT (Valsartan in Acute
Figure 4 Survival of Patients Prescribed a WCD
Kaplan-Meier survival curves for all post-myocardial infarction patients (N ¼ 6,575
with Social Security Number or known death) (A), and for the subgroup who
received appropriate wearable cardioverter-deﬁbrillator (WCD) shock therapy
(n ¼ 133) (B).
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2005Myocardial Infarction Trial) (1), DINAMIT (4), and the
IRIS (5) studies. In VALIANT, 14,703 patients were
randomized to receive valsartan, captopril, or both after MI
complicated by heart failure, a low LVEF, or both (1). It was
shown that 7% either died suddenly (6%) or were resusci-
tated from cardiac arrest (1%) at a median time of 180 days
during a median follow-up of 24.7 months. The cumulative
event rate was 1.4% (19% of the events in the trial) in the
ﬁrst 30 days, and 2.5% between 1 and 6 months. Of those
resuscitated in the ﬁrst month, 74% were alive 1 year later.
For patients with heart failure, the risk of death was 4 to 6
times higher than those without heart failure (1,8). In our
population, 1.6% of patients had events with a mean of 22
days to shock (30 days from MI), very similar to the event
rate in VALIANT. Nevertheless, in VALIANT, sudden
unexpected deaths were reported without veriﬁcation that
they were indeed arrhythmic, and autopsy ﬁndings from
a substudy suggest that only about 50% of post-MI sudden
deaths were likely arrhythmic (9). The present study may
provide a more accurate assessment of true arrhythmic
events. In the present study, and similar to VALIANT,
shocked patients who survived the initial event had a 1-year
survival of 71%.Results from the DINAMIT and IRIS studies have led to
the speculation that in patients early post-MI, deﬁbrillation
may not improve overall survival because they have a high
risk of death from other cardiac causes. In DINAMIT,
patients with a LVEF 35% and abnormal autonomic
function between 6 and 40 days post-MI were randomized to
OMT with or without an ICD. Survival in both groups was
identical (4). In the IRIS study, patients with a LVEF40%
and a heart rate>90 beats/min with or without nonsustained
VT 5 to 31 days post-MI on OMT were randomized to
receive an ICD or not. Identical to DINAMIT, the
IRIS study showed no survival beneﬁt with ICD therapy. and
as inDINAMIT, the reduction in SCDby the ICDwas offset
by a parallel increase in nonsudden death (5).
To further place our data in perspective, the annual
mortality rate in DINAMIT for both the control and ICD
groups was approximately 7.2% or, assuming a linear
mortality rate, 1.8% in the ﬁrst 3 months (4). In the IRIS
study, approximately 11.6% died during the ﬁrst year of
follow-up or, again assuming a linear mortality rate, 2.9% in
the ﬁrst 3 months (5). In DINAMIT, the mean time from
index MI to randomization was 18 days, and an average of
6 more days to ICD implantation (4). In the IRIS study,
however, 91.1% of the patients who received an ICD did so
in the index hospitalization (5). The differences in proximity
to the index MI when patients were enrolled in the 2 studies
may partly explain differences in mortality in the ﬁrst
3 months. Furthermore, because mortality risk is generally
highest in the immediate post-MI period, these linear
interpolations may underestimate the risk. Withstanding
these limitations, the overall mortality of 4% at 3 months in
our entire population is higher than the death rates in both
the DINAMIT and IRIS studies, attesting to their having
been selected for particularly high risk.
The failure of ICD therapy to provide beneﬁt when
implanted early after MI was foreshadowed by MADIT II
(Multicenter Automatic Deﬁbrillator Implantation Trial)
(10). In the MADIT II trial, which required a waiting
period of 1 month post-MI and 3 months if revasculariza-
tion had been undertaken, ICD beneﬁt only occurred
9 months after randomization in the trial. At 3 months
following enrollment, about 4% of the patients had died in
both the ICD and medical therapy groups. The survival
curves only began to diverge at 9 months. Notably, in long-
term follow-up, only if implantation occurred >18 months
from the last MI was ICD beneﬁt apparent (11).
Because ICD trials were designed to address long-term
mortality, interpretation of the results of this study, which
address the short-term risk of SCA, in the context of ICD
data is challenging. In both the DINAMIT and IRIS
studies, the decrease in arrhythmic mortality was exactly
counterbalanced by nonarrhythmic mortality in the ICD
group (4,5). Furthermore, after appropriate shocks for VT/
VF in DINAMIT, mortality was 30% at 1 year (4); simi-
larly, in MADIT II, mortality was 20% 1 year after appro-
priate therapy (10). In the present study, mortality 1 year
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2006after treatment was 29%. The true advantage of WCD
therapy is that because the LVEF signiﬁcantly improves
with OMT over the initial 8 to 12 weeks after MI, for those
surviving, it may improve to a point where an ICD is not
indicated. In the HEART (Healing and Early Afterload
Reducing Therapy) study (12), 66% of patients had
improvement in the LVEF by day 90 (mean absolute
improvement 4.5%), and the REFINE (Risk Estimation
Following Infarction, Noninvasive Evaluation) study
demonstrated the absolute improvement in the LVEF was
18% at 8 weeks (13). Although some may argue that
prescription of a deﬁbrillator, whether an ICD or WCD, is
not appropriate during the waiting period post-MI, as LV
function improves, our study suggests that a small, but not
necessarily unimportant, group of patients may derive
beneﬁt from deﬁbrillation early after MI.
It is important to note that access to rapid deﬁbrillation
does not necessarily ensure SCA survival, because 0.4% of
the patients in the present study died from bradycardia or
asystole. This is in keeping with the VALIANT substudy
referenced earlier in the text in which Pouleur et al. (9)
showed that of 105 SCDs, 51 of the patients had speciﬁc
ﬁndings such that their deaths, without autopsy, would have
been deemed arrhythmic, most commonly recurrent MI (31
patients) or cardiac rupture (13 patients). Although sudden
death due to recurrent MI or rupture was highest in the ﬁrst
month in VALIANT, it then declined. Arrhythmic deaths,
however, increased over time, from 20% in the ﬁrst month
to 75% later in the study (9). Finally, Chung et al. (7) re-
ported the aggregate national experience with a WCD in
2010. Of 3,569 patients wearing the device, daily use
was 19.9  4.7 h per day, and >90% of the day in 52% of
the patients. Although ﬁrst-shock success was 100% for
unconscious VT/VF, 8 patients died after successful shock
therapy. In addition, asystole occurred in 23 patients (0.6%),
of whom 17 died, pulseless electrical activity occurred in
2, and respiratory arrest occurred in 1, representing 24.5%
of SCAs, in keeping with the data mentioned in the previous
text, attesting to the fact that many apparently sudden
deaths are either noncardiac or from nonshockable rhythms.
These ﬁndings may help explain the results of DINAMIT,
IRIS, and our study.
The automated external deﬁbrillator (AED) also may be
considered for the purpose of bridging therapy in a nonin-
vasive manner during waiting periods (14–16). Although it
has proven beneﬁt in public areas (17,18), about 75% of
cardiac arrests occur at home (19,20), and often in the
absence of a witness who can deploy the device (21). In the
HAT (Home Automated External Deﬁbrillator Trial), for
survivors of anterior-wall MI who were not candidates for
ICD implantation, a home AED did not signiﬁcantly
improve overall survival compared with conventional care
(16). Thus, having a wearable device that automatically
provides monitoring and delivers electrical therapy without
bystander intervention avoids some limitations of AED use
and may be useful in that regard.A unique aspect of this database gives insight into the
arrhythmias that lead to SCA in the contemporary, ambu-
latory setting. Prior data obtained from Holter recordings
varied in the distribution of terminal rhythms at the time
of death. Bayés de Luna et al. (22) reported that VT
degenerated into VF in 62% of the recordings, and 21%
had VF or torsade de pointes VT as the initiating and
treated arrhythmia. Pratt et al. (23) and Panidis and Mor-
ganroth (24) reported that VF was always preceded by VT or
VFl. Our contemporary data show that MVT degenerated
into VF in only 7.5% of the recordings, but that at onset
and treatment, MVT was present in 50%, and PMVT or
VF was present in 38% of the recordings. Interestingly,
survival was not inﬂuenced by differences in the presenting
or treated arrhythmia. The median time to therapy of 47 s
is also notable. First, this suggests that therapy was not
overly aggressive. Second, having a delay before therapy is
in keeping with the excellent outcomes reported by
the MADIT-RIT (Multicenter Automatic Deﬁbrillator
Implantation Trial–Reduction in Inappropriate Therapy) in
which ICDs were programmed to have a delay in therapy
(25), and a substudy of the DEFINITE (Deﬁbrillators in
Non-ischemic Cardiomyopathy Treatment Evaluation)
study in which Ellenbogen et al. (26) proposed that the
equal rates of syncope and ICD shocks in the control and
ICD groups suggests that given time, many arrhythmias
spontaneously terminate. Finally, the treatment rate of 1.6%
is much lower than the appropriate shock rate in the
DINAMIT and IRIS studies, also attesting to the absence
of overtreatment.
Study limitations. Our study is purely observational,
derived from the manufacturer’s database. In addition to
the absence of a control group who received medical care
without a WCD, other limitations are present. First, the
database for the WCD, by necessity, included only limited
patient information. Speciﬁc information regarding the
medical therapy provided, comorbidity, and clinical reasons
why individuals may have been chosen for a WCD are
unknown. Indeed, precise data regarding myocardial
function beyond the LVEF are unknown. Furthermore, the
LVEF was determined from chart review only for patients
who were treated or died. To get information on the
patients who survived and did not receive WCD treatment
would require chart review, which is not feasible. In
addition, the frequency of pre-existing LV dysfunction,
prior MI, current functional class, and scar burden are
unknown, all factors that inﬂuence outcome. Second, shock
success, even though delivered to unconscious patients
during a sustained ventricular arrhythmia, is an imperfect
surrogate for resuscitation from certain arrhythmic death
(27). Third, quality-of-life data are not available in our
study, and the psychological impact of using a WCD
post-MI was not assessed, especially important because
depression and anxiety frequently occur during this time.
Fourth, the management and outcomes of patients resus-
citated by the WCD are unknown because this information
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2007was not part of the manufacturer’s database. Fifth, cost
effectiveness could not be assessed due to the nature of the
database. Finally, in 2012, protected state death records
were removed from the SSDMF database, which dimin-
ished our ability to determine survival in patients.
Conclusions
To our knowledge, this is the only report that describes
use of the WCD in patients early post-MI perceived to be
at high risk for SCA, a population currently not covered
for ICD implantation. That 1.4% of patients may be
successfully treated in the ﬁrst 3 months with a resuscita-
tion survival rate of 91% implies that a select group of
patients may beneﬁt from deﬁbrillation early after MI,
particularly during the ﬁrst 30 days following hospital
discharge. These survivors may then receive an ICD.
Further study of WCD use for the prevention of SCD
is warranted in the critical period early post-MI.
The ongoing Vest Prevention of Early Sudden Death
Trial and VEST Registry (ClinicalTrials.gov identiﬁer
NCT01446965) will help to answer that question.
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